Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising

FDA approves Celgene’s R2 for two types of indolent lymphoma

pharmaceutical-technologyMay 30, 2019

Tag: FDA , Celgene , indolent lymphoma

PharmaSources Customer Service